SHARPE
Reported results
- Global VYJUVEK net product revenue for the third quarter of 2026 was $127.3 million, an increase of 30% compared to the prior year third quarter.
- Net income for the third quarter ended September 30, 2026 was $63.1 million, or $2.13 per common share (basic) and $2.05 per common share (diluted).
- Cost of goods sold totaled $7.6 million for the third quarter ended September 30, 2026.
- Research and development expenses for the third quarter ended September 30, 2026 were $14.9 million, inclusive of $2.6 million of stock-based compensation.
- Selling, general, and administrative expenses for the third quarter ended September 30, 2026 were $33.7 million, inclusive of stock-based compensation of $11.3 million.
- Cash, cash equivalents and investments totaled $1.2 billion as of September 30, 2026.
Guidance
- Full Year 2026 Non-GAAP Research and Development (“R&D”) and Selling, General and Administrative (“SG&A”) expense is expected to be in the range of $155.0 million - $165.0 million.
Price and volatility reaction
The stock moved -10.9% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +25.2 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 332.29 | 2026-10-30 |
| Close after release | 295.9 | 2026-11-02 |
| Realised move | -10.9% | close to close |
| 30d ATM IV change | +25.2 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-02 (8-K, Item 2.02). Read the original filing on sec.gov.